DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Bharat Bijlee Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·9 Oct 2026, 10:48 am

Bharat Bijlee

Bharat Bijlee Limited has informed the stock exchanges about the issuance of a compliance certificate for the quarter ended September 30, 2026. This document confirms that the company has adhered to the regulations set forth by SEBI regarding its depository participants. It is a standard procedural update required for listed entities to maintain transparency with the market.

For investors, this announcement is a routine corporate disclosure and does not indicate any material operational changes or financial results. It serves as a confirmation of the company's compliance status with regulatory norms. The stock is likely to see no significant movement based on this information alone.

Investors should look for the company's upcoming quarterly results and operational performance to gauge the stock's future direction, rather than focusing on this regulatory filing.